WO2002046238A3 - Rationally designed antibodies - Google Patents

Rationally designed antibodies Download PDF

Info

Publication number
WO2002046238A3
WO2002046238A3 PCT/US2001/047656 US0147656W WO0246238A3 WO 2002046238 A3 WO2002046238 A3 WO 2002046238A3 US 0147656 W US0147656 W US 0147656W WO 0246238 A3 WO0246238 A3 WO 0246238A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
rationally designed
fragments
designed antibodies
terminal
Prior art date
Application number
PCT/US2001/047656
Other languages
French (fr)
Other versions
WO2002046238A2 (en
Inventor
Katherine S Bowdish
Shana Barbas-Frederickson
Mark Renshaw
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Priority to AU2002234001A priority Critical patent/AU2002234001B2/en
Priority to AU3400102A priority patent/AU3400102A/en
Priority to CA2436671A priority patent/CA2436671C/en
Priority to DE60118023T priority patent/DE60118023T2/en
Priority to EP01985007A priority patent/EP1370589B1/en
Publication of WO2002046238A2 publication Critical patent/WO2002046238A2/en
Publication of WO2002046238A3 publication Critical patent/WO2002046238A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/14—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

Antibodies or fragments thereof having CDR regions replaced or fused with biologically active peptides are described. Flanking sequences may optionally be attached at one or both the carboxy-terminal and amino-terminal ends of the peptide in covalent association with adjacent framework regions. Compositions containing such antibodies or fragments thereof are useful in therapeutic and diagnostic modalities.
PCT/US2001/047656 2000-12-05 2001-12-05 Rationally designed antibodies WO2002046238A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2002234001A AU2002234001B2 (en) 2000-12-05 2001-12-05 Rationally designed antibodies
AU3400102A AU3400102A (en) 2000-12-05 2001-12-05 Rationally designed antibodies
CA2436671A CA2436671C (en) 2000-12-05 2001-12-05 Rationally designed antibodies
DE60118023T DE60118023T2 (en) 2000-12-05 2001-12-05 RATIONELALLY DESIGNED ANTIBODIES
EP01985007A EP1370589B1 (en) 2000-12-05 2001-12-05 Rationally designed antibodies

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US25144800P 2000-12-05 2000-12-05
US60/251,448 2000-12-05
US28888901P 2001-05-04 2001-05-04
US60/288,889 2001-05-04
US29406801P 2001-05-29 2001-05-29
US60/294,068 2001-05-29

Publications (2)

Publication Number Publication Date
WO2002046238A2 WO2002046238A2 (en) 2002-06-13
WO2002046238A3 true WO2002046238A3 (en) 2003-07-10

Family

ID=27400449

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/047656 WO2002046238A2 (en) 2000-12-05 2001-12-05 Rationally designed antibodies

Country Status (11)

Country Link
US (3) US7482435B2 (en)
EP (4) EP1370589B1 (en)
AT (3) ATE320450T1 (en)
AU (2) AU2002234001B2 (en)
CA (1) CA2436671C (en)
CY (1) CY1112639T1 (en)
DE (2) DE60118023T2 (en)
DK (1) DK1642910T3 (en)
ES (3) ES2316919T3 (en)
PT (1) PT1642910E (en)
WO (1) WO2002046238A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2388341T3 (en) 1998-10-23 2012-10-11 Kirin-Amgen Inc. Dimeric thrombopoietin mimetic peptides that bind to the MPL receptor and that have thrombopoietic activity
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
AU2003295623B2 (en) * 2000-12-05 2008-06-05 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
DE60118023T2 (en) * 2000-12-05 2006-12-28 Alexion Pharmaceuticals, Inc., Cheshire RATIONELALLY DESIGNED ANTIBODIES
US7332474B2 (en) * 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
JP2006504406A (en) * 2002-06-28 2006-02-09 セントカー・インコーポレーテツド Mammalian CH1-deficient mimetibodies, compositions, methods and uses
UA89481C2 (en) * 2003-09-30 2010-02-10 Центокор, Инк. Human epo mimetic hinge core mimetibodies, compositions, methods and uses
JP4767857B2 (en) * 2003-09-30 2011-09-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Benzimidazole compounds
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US20070116710A1 (en) * 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
US7393662B2 (en) 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
SI2359834T1 (en) * 2006-03-15 2017-02-28 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
JP2010515463A (en) * 2007-01-12 2010-05-13 シー レーン バイオテクノロジーズ， エルエルシー Combinatorial library of conformationally constrained polypeptide sequences
US20090022729A1 (en) * 2007-04-13 2009-01-22 Nigel Mackman Methods and compositions for treating cardiac dysfunctions
WO2008157824A2 (en) * 2007-06-21 2008-12-24 Conjuchem Biotechnologies Inc. Thrombopoietin peptide conjugates
RS64039B1 (en) 2008-11-10 2023-04-28 Alexion Pharma Inc Methods and compositions for treating complement-associated disorders
NZ603712A (en) * 2009-02-24 2014-05-30 Alexion Pharma Inc Antibodies containing therapeutic tpo/epo mimetic peptides
EP2595657A4 (en) 2010-07-22 2015-09-23 Univ California Anti-tumor antigen antibodies and methods of use
TW201241008A (en) * 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
AU2011329647B2 (en) 2010-11-19 2015-10-22 Eisai R&D Management Co., Ltd. Neutralizing anti-CCL20 antibodies
AP2015008365A0 (en) 2012-12-05 2015-04-30 Novartis Ag Compositions and methods for antibodies targeting epo
US20150079613A1 (en) 2013-08-07 2015-03-19 Ryan Kitchel Atypical hemolytic uremic syndrome biomarker proteins
CA2971288A1 (en) 2015-02-02 2016-08-11 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes
JP2018525389A (en) 2015-08-12 2018-09-06 ノバルティス アーゲー How to treat eye disorders
PE20181358A1 (en) * 2015-12-04 2018-08-22 Novartis Ag COMPOSITIONS OF ANTIBODY GRAFTED WITH CYTOKINE AND METHODS FOR ITS USE IN IMMUNOREGULATION
CN108473987B (en) 2016-01-08 2024-01-02 马可讯治疗有限公司 Binding members with altered diverse scaffold domains
JOP20190271A1 (en) 2017-05-24 2019-11-21 Novartis Ag Antibody-cytokine engrafted proteins and methods of use for immune related disorders
WO2019012015A1 (en) 2017-07-12 2019-01-17 Iontas Limited Potassium channel inhibitors
GB201711208D0 (en) 2017-07-12 2017-08-23 Iontas Ltd Ion channel inhibitors
CN108623681B (en) * 2018-05-04 2019-05-24 珠海泰诺麦博生物技术有限公司 A kind of neutralizing antibody of anti-tetanus toxin and application
UY38747A (en) 2019-06-12 2021-01-29 Novartis Ag NATRIURETIC 1 PEPTIDE RECEPTOR ANTIBODIES AND METHODS OF USE

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011317A1 (en) * 1993-10-19 1995-04-27 The Scripps Research Institute Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus
WO1995029690A1 (en) * 1994-04-29 1995-11-09 The Trustees Of The University Of Pennsylvania Biologically active peptides and methods of identifying the same
WO1996040189A1 (en) * 1995-06-07 1996-12-19 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5773569A (en) * 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
WO1999010494A2 (en) * 1997-08-25 1999-03-04 Genentech, Inc. Agonist antibodies to the thrombopoietin receptor, and their therapeutic uses
WO1999025378A1 (en) * 1997-11-14 1999-05-27 Euro-Celtique, S.A. Immunoglobulin molecules having a synthetic variable region and modified specificity
WO2000024782A2 (en) * 1998-10-23 2000-05-04 Amgen Inc. Modified peptides, comprising an fc domain, as therapeutic agents
WO2000061637A1 (en) * 1999-04-14 2000-10-19 Smithkline Beecham Corporation Erythropoietin receptor antibodies
WO2002078612A2 (en) * 2001-04-02 2002-10-10 Euro-Celtique S.A. Thrombopoietin (tpo) synthebody for stimulation of platelet production

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0088994B1 (en) * 1982-03-15 1991-06-19 Schering Corporation Hybrid dna, binding composition prepared thereby and processes therefor
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4783330A (en) * 1984-11-15 1988-11-08 New England Medical Center Hospitals, Inc. Monoclonal antibodies to activated platelets
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5965405A (en) * 1988-04-16 1999-10-12 Celltech Limited Method for producing Fv fragments in eukaryotic cells
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5750373A (en) * 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US20020086843A1 (en) * 1989-03-01 2002-07-04 Daiichi Pure Chemicals Co., Ltd. Physiologically active polypeptide and DNA
US5260417A (en) * 1989-04-03 1993-11-09 Genetics Institute, Inc. Megakaryocyte growth promoting activity protein
US6172197B1 (en) * 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE196548T1 (en) * 1991-05-10 2000-10-15 Genentech Inc SELECTING AGONISTS AND ANTAGONISTS OF LIGANDS
EP0523949B1 (en) * 1991-07-15 2003-06-25 The Wellcome Foundation Limited Production of antibodies
JP2665850B2 (en) * 1991-11-14 1997-10-22 塩野義製薬株式会社 Monoclonal antibody recognizing the C-terminus of hBNP
AU4190893A (en) * 1992-07-17 1994-01-20 Suntory Limited Megakaryocyte differentiation factor
US6955900B1 (en) * 1993-02-02 2005-10-18 The Scripps Research Institute Methods for producing polypeptide binding sites, monoclonal antibodies and compositions thereof
US5598435A (en) * 1993-12-23 1997-01-28 British Telecommunications Public Limited Company Digital modulation using QAM with multiple signal point constellations not equal to a power of two
US5919758A (en) * 1994-03-22 1999-07-06 Beth Israel Deaconess Medical Center Modified polypeptides with altered biological activity
US5885574A (en) * 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5593666A (en) * 1994-08-16 1997-01-14 The University Of Tennessee Research Corp. Methods and compositions for treating thrombocytopenia
DE19513676A1 (en) * 1995-04-11 1996-10-17 Behringwerke Ag Cytoplasmic expression of antibodies, antibody fragments and antibody fragment fusion molecules in E. coli
EP2338897A1 (en) * 1995-06-07 2011-06-29 Glaxo Group Limited Peptides and compounds that bind to a thrombopoietin receptor
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
PT914344E (en) * 1996-03-04 2005-10-31 Scios Inc TEST AND REAGENTS FOR HBNP QUANTIFICATION
US5932546A (en) * 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
US6737249B1 (en) * 1997-08-22 2004-05-18 Genentech, Inc. Agonist antibodies
AUPP221098A0 (en) * 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
ES2388341T3 (en) * 1998-10-23 2012-10-11 Kirin-Amgen Inc. Dimeric thrombopoietin mimetic peptides that bind to the MPL receptor and that have thrombopoietic activity
DE60118023T2 (en) 2000-12-05 2006-12-28 Alexion Pharmaceuticals, Inc., Cheshire RATIONELALLY DESIGNED ANTIBODIES
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011317A1 (en) * 1993-10-19 1995-04-27 The Scripps Research Institute Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus
US5773569A (en) * 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
WO1995029690A1 (en) * 1994-04-29 1995-11-09 The Trustees Of The University Of Pennsylvania Biologically active peptides and methods of identifying the same
WO1996040189A1 (en) * 1995-06-07 1996-12-19 Glaxo Group Limited Peptides and compounds that bind to a receptor
WO1999010494A2 (en) * 1997-08-25 1999-03-04 Genentech, Inc. Agonist antibodies to the thrombopoietin receptor, and their therapeutic uses
WO1999025378A1 (en) * 1997-11-14 1999-05-27 Euro-Celtique, S.A. Immunoglobulin molecules having a synthetic variable region and modified specificity
WO2000024782A2 (en) * 1998-10-23 2000-05-04 Amgen Inc. Modified peptides, comprising an fc domain, as therapeutic agents
WO2000061637A1 (en) * 1999-04-14 2000-10-19 Smithkline Beecham Corporation Erythropoietin receptor antibodies
WO2002078612A2 (en) * 2001-04-02 2002-10-10 Euro-Celtique S.A. Thrombopoietin (tpo) synthebody for stimulation of platelet production

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHAIKEN I M ET AL: "Identifying structure-function relationships in four-helix bundle cytokines: towards de novo mimetics design", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 14, no. 10, 1 October 1996 (1996-10-01), pages 369 - 375, XP004035727, ISSN: 0167-7799 *
COOK J ET AL: "Recombinant antibodies containing an engineered B-cell epitope capable of eliciting conformation-specific antibody responses", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 13, no. 18, 1995, pages 1770 - 1778, XP004057383, ISSN: 0264-410X *
DENG B ET AL: "An agonist murine monoclonal antibody to the human c-mpl receptor stimulates in vitro megakaryocytopoiesis", EXPERIMENTAL HEMATOLOGY, NEW YORK, NY, US, vol. 24, no. 9, 1 August 1996 (1996-08-01), pages 260, XP002095741, ISSN: 0301-472X *
HAYDEN M S ET AL: "Antibody engineering", CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD, XX, vol. 9, no. 2, April 1997 (1997-04-01), pages 201 - 212, XP004327252, ISSN: 0952-7915 *
JAGERSCHMIDT ALEXANDRE ET AL: "Human thrombopoietin structure-function relationships: Identification of functionally important residues.", BIOCHEMICAL JOURNAL, vol. 333, no. 3, 1 August 1998 (1998-08-01), pages 729 - 734, XP002234914, ISSN: 0264-6021 *
KAMURA TAKUMI ET AL: "Characterization of the human thrombopoietin gene promoter: A possible role of an Ets transcription factor E4TF1/GABP.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 17, 1997, pages 11361 - 11368, XP002224664, ISSN: 0021-9258 *
MONFARDINI CRISTINA ET AL: "Recombinant antibodies in bioactive peptide design.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 12, 1995, pages 6628 - 6638, XP002224663, ISSN: 0021-9258 *
PARHAMI-SEREN B ET AL: "Selection of high affinity p-azophenyarsonate Fabs from heavy-chain CDR2 insertion libraries", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 259, no. 1-2, 1 January 2002 (2002-01-01), pages 43 - 53, XP004324199, ISSN: 0022-1759 *

Also Published As

Publication number Publication date
US20100041012A1 (en) 2010-02-18
DK1642910T3 (en) 2012-05-07
EP1498429A3 (en) 2005-08-03
EP1642910B1 (en) 2012-02-08
EP1370589A2 (en) 2003-12-17
EP1589034A3 (en) 2005-11-02
ES2316919T3 (en) 2009-04-16
EP1370589B1 (en) 2006-03-15
WO2002046238A2 (en) 2002-06-13
AU2002234001B2 (en) 2008-05-01
EP1642910A1 (en) 2006-04-05
CY1112639T1 (en) 2016-02-10
ATE414720T1 (en) 2008-12-15
DE60118023D1 (en) 2006-05-11
EP1589034A2 (en) 2005-10-26
DE60118023T2 (en) 2006-12-28
DE60136656D1 (en) 2009-01-02
US20150004700A1 (en) 2015-01-01
ATE544785T1 (en) 2012-02-15
CA2436671C (en) 2015-02-03
PT1642910E (en) 2012-03-22
US7482435B2 (en) 2009-01-27
EP1589034B1 (en) 2008-11-19
US9409964B2 (en) 2016-08-09
CA2436671A1 (en) 2002-06-13
ES2380367T3 (en) 2012-05-11
US20030049683A1 (en) 2003-03-13
AU3400102A (en) 2002-06-18
EP1498429A2 (en) 2005-01-19
US8771932B2 (en) 2014-07-08
ES2258558T3 (en) 2006-09-01
ATE320450T1 (en) 2006-04-15

Similar Documents

Publication Publication Date Title
EP1498429A3 (en) Rationally designed antibodies
WO2005060642A3 (en) Rationally designed antibodies
WO2004050017A3 (en) Rationally designed antibodies
WO2005082004A3 (en) Rationally designed antibodies having a domain-exchanged scaffold
IL195649A0 (en) Compositions comprising anti-??v??3 recombinant human antibodies and nucleic acids encoding the same
HK1109160A1 (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
IL138212A0 (en) Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities
IL160001A0 (en) Peptide based multimeric targeted contrast agents and methods for the preparation thereof
HK1043798A1 (en) Recombinant il-18 antibodies and their use
HK1135330A1 (en) Short bioactive peptides and methods for their use
WO2002102828A3 (en) Chimeric flavivirus vectors
CA2253837A1 (en) Therapeutic uses of bpi protein products for human meningococcemia
GB0216972D0 (en) Peptides and peptide derivaties for the treatment of &-synuclein-related diseases
IL152202A0 (en) Human kcnq5 polypeptide and pharmaceutical compositions containing the same
AU2002233424A1 (en) Peptides having affinity for the GP120 viral protein and use thereof
WO2004108078A3 (en) Rationally designed antibodies
GB9918155D0 (en) Proteins and peptides
AU4293600A (en) Recombinant protein uk114 and its use in therapy and diagnostics
Critical Care Society of South Africa Working Group Severe sepsis and the role of novel therapeutic agents. Position statement of the Critical Care Society of South Africa on severe sepsis and the role of novel therapeutic agents such as drotrecogin alfa (activated)
AU2002212776A1 (en) C-terminal region protein of the human nucleolar phosphoprotein hnopp 140 that specifically interact with doxorubicin and the gene thereof
HK1044796A1 (en) Nucleic acids coding for novel truncated cart proteins, corresponding truncated cart polypeptides and their use for therapeutic and diagnostic purposes
AU2002349719A1 (en) The use of osteogenic growth peptide in the enhancement of haemopoiesis
AU2001270794A1 (en) Short peptides comprising histidine or alanine and their therapeutic use
AU4580600A (en) Nucleic acids coding for novel truncated cart proteins, corresponding truncated cart polypeptides and their use for therapeutic and diagnostic purposes
ATA19362001A (en) NUCLEIC ACID BINDING PEPTIDES AND THE USE OF SUCH PEPTIDES IN PHARMACEUTICAL PREPARATIONS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002234001

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2436671

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002547974

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001985007

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001985007

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2001985007

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP